CompletedPhase 2NCT00634244
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Mark Litzow, M.DECOG-ACRIN Cancer Research Group
- Intervention
- alvocidib(drug)
- Enrollment
- 92 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2008 – 2014
Study locations (20)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- The Jewish Hospital, Cincinnati, Ohio, United States
- Geisinger Medical Center, Danville, Pennsylvania, United States
- Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States
- Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Lewistown Hospital, Lewistown, Pennsylvania, United States
- Geisinger Medical Group, State College, Pennsylvania, United States
- Mount Nittany Medical Center, State College, Pennsylvania, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00634244 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.